By Fineline Cube 
Sirnaomics Ltd. (HKG: 2257) announced a global non‑exclusive licensing agreement with ChemPartner Co., Ltd. (SHE: 300149), focusing on GalAhead and related nucleic acid drug delivery technology platforms to create a comprehensive service channel for small nucleic acid drug development.
Agreement Overview & Strategic Focus
| Element | Details |
|---|---|
| Companies | Sirnaomics Ltd. (2257.HK) + ChemPartner |
| Agreement Type | Global non-exclusive licensing |
| Technology | GalAhead delivery platform + nucleic acid drug delivery |
| Target Organ | Liver-targeted delivery |
| Key Features | Long-acting drug administration capabilities |
| ChemPartner Role | CRO/CDMO providing full-cycle integrated services |
GalAhead Platform & Technology Differentiation
Sirnaomics’ GalAhead Platform:
- Liver-Targeted Delivery: Specifically designed for hepatic tissue targeting
- Long-Acting Formulation: Meets requirements for extended dosing intervals
- Nucleic Acid Focus: Optimized for siRNA, antisense oligonucleotides, and other RNA therapeutics
- Competitive Edge: Addresses key delivery challenges in nucleic acid drug development
ChemPartner’s Contribution:
- Full-Cycle CRO/CDMO: Covers discovery through commercial manufacturing
- Integrated Services: Streamlines development process for biotech partners
- Platform Synergy: Combines delivery technology with development expertise
Strategic Rationale & Market Impact
| Strategic Goal | Mechanism | Expected Outcome |
|---|---|---|
| Comprehensive Service Channel | Integrate GalAhead with ChemPartner’s CRO/CDMO | End-to-end nucleic acid drug development capability |
| Industry Empowerment | Provide accessible delivery technology platform | Accelerate innovation across biotech sector |
| Global Expansion | Non-exclusive licensing enables multiple partnerships | Drive high-quality development of nucleic acid therapeutics |
| Quality Development | Combine technology strengths | Establish new standard for RNA therapeutic development |
Market Context & Competitive Landscape
- Nucleic Acid Drug Market: Global market projected $15 billion by 2030, growing at 25% CAGR
- Delivery Challenge: Liver targeting remains key bottleneck; GalAhead addresses this specifically
- CRO/CDMO Demand: China biotech sector driving demand for integrated nucleic acid development services
- Sirnaomics Portfolio: Company has multiple siRNA candidates in clinic; platform licensing diversifies revenue
- ChemPartner Strategy: Partnership enhances capability in high-growth RNA therapeutics segment
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration’s impact on nucleic acid drug development, commercial prospects, and market penetration. Actual results may differ due to technology adoption rates, competitive dynamics, and regulatory uncertainties.-Fineline Info & Tech